Emcure Pharma Q3 Results: Net profit rises 35% to Rs 154 crore

Pharma

Emcure Pharma on February 6 reported a net profit of Rs 153.72 crore for the third quarter of the current financial year. This marks a rise of over 35 percent from the Rs 113.45 crore net profit reported in Q3 of previous financial year.

Its revenue from operations meanwhile jumped nearly 18 percent year-on-year to Rs 1,962.63 crore during the reported quarter. It had reported revenue from operations at Rs 1,667.64 crore in the corresponding period of the previous financial year.

Also read: Our LIVE blog on Q3 results

Emcure Pharma’s total income rose 17 percent year-on-year to Rs 1,966.5 crore in Q3 FY25 from Rs 1,683.36 crore in Q3 FY24. Its total expenses stood at Rs 1,736.6 crore during the reported quarter.

"The Canadian business continues to perform well, achieving a 34% YoY growth and the Mantra subsidiary is now fully integrated. Company’s Rest of the World (RoW) market business grew a robust 40% YoY aided by strong growth in our non-ARV segment. The company continues to see traction in its key focus markets led by its differentiated product portfolio. Emcure’s Domestic business grew by over 12% to ₹ 888 Cr, led by a steady performance in the base business and aided by in-licensed products," the company said in its press release.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said, "Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on back of our differentiated product portfolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portfolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies."

The shares of the company closed nearly 3 percent higher at Rs 1,286 apiece on February 6. The stock had debuted on the bourses with 32 percent premium over the issue price at Rs 1,325.05 on July 10, 2024. It has however fallen nearly 3 percent from that level.